A5025971587- Pharmaceutical studies and practices
- Heart Failure Treatment and Management
- Pharmacogenetics and Drug Metabolism
- Cardiovascular Function and Risk Factors
- Pharmacological Effects and Toxicity Studies
- Electrochemical Analysis and Applications
- Pharmaceutical Practices and Patient Outcomes
- Diabetic Foot Ulcer Assessment and Management
- Zebrafish Biomedical Research Applications
- Birth, Development, and Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Nanoparticles: synthesis and applications
- Cardiac Ischemia and Reperfusion
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- BRCA gene mutations in cancer
- Angiogenesis and VEGF in Cancer
- Environmental Toxicology and Ecotoxicology
- Salivary Gland Disorders and Functions
- Medication Adherence and Compliance
- Diabetes Management and Research
Taipei Medical University Hospital
2021-2025
Taipei Medical University
2021-2025
Cardiovascular Research Center
2024
In diabetes (DM), elevated blood sugar levels contribute to the overproduction of reactive oxygen species (ROS), leading endothelial progenitor cell (EPC) dysfunction. This study aimed determine potential 2-hydroxy hispolon (2HH), a derivative hispolon, reverse high glucose-induced EPC Under in vitro high-glucose (HG) conditions, we investigated effects 2HH on three types angiogenic cells: outgrowth cells (OECs), circulating (CACs) and (ECs). vivo, high-fat diet streptozotocin-induced...
Sacubitril/valsartan (Entresto) has proven therapeutic effects in heart failure (HF) patients, but its impact on those with advanced chronic kidney disease (CKD) remains unclear, particularly HF patients coexisting end-stage renal (ESRD). This study aims to assess the long-term survival of reduced ejection fraction (HFrEF) and ESRD treated sacubitril/valsartan. A retrospective cohort included 2,860 HFrEF between January 2008 December 2020. After propensity score matching, data from a...
The aim of this study was to evaluate the potential associations between Sjogren syndrome and outcomes acute myocardial infarction (AMI) hospitalization. This population-based, retrospective observational extracted data from US Nationwide Inpatient Sample 2005 2018. Adults aged 20 years or older hospitalized for AMI were eligible inclusion. Propensity score matching applied balance characteristics comparison groups (ie, with without syndrome). Associations in-hospital determined using...
Statins, beta-blockers, and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers have been advocated by guidelines as secondary prevention medications to improve the long-term outcomes of post-acute myocardial infarction (AMI) patients. However, adequate drug adherence has always challenging, different treatment regimens may lead divergent that remain unclear under current (MI) care standards. This study investigated association between use preventive post-AMI patients'...
ABSTRACT Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcome by choosing the medication and dosage optimized for a patient based on genetic factors that affect drug response 1 . One of most promising benefits PGx-guided therapy is avoidance adverse reactions 2 To evaluate impact PGx risk variants outcomes, we performed retrospective study analyzed data from largest Han Chinese cohort assembled Taiwan Precision Medicine Initiative. We found nearly all...
<title>Abstract</title> Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcome by choosing the medication and dosage optimized for a patient based on genetic factors that affect drug response<sup>1</sup>. One of most promising benefits PGx-guided therapy is avoidance adverse reactions<sup>2</sup>. To evaluate impact PGx risk variants outcomes, we performed retrospective study analyzed data from largest Han Chinese cohort assembled Taiwan Precision...